Spilled Blood: CSL & Talecris Terminate Their Merger Deal In Face of FTC Lawsuit
This article was originally published in PharmAsia News
Executive Summary
Caving in to opposition from the Federal Trade Commission, CSL Limited has scuttled its $3.1 billion deal to acquire Talecris Biotherapeutics, saying it was not worth the money and time to battle the agency in court
You may also be interested in...
CSL Releases First Corporate Responsibility Report; Highlights Access To Medicines, Environmental Impact And Compliance
PERTH, Australia - Melbourne-headquartered CSL March 29 released its first Corporate Responsibility Report, combining information about the company's economic, social and environmental performance for 2009
CSL Releases First Corporate Responsibility Report; Highlights Access To Medicines, Environmental Impact And Compliance
PERTH, Australia - Melbourne-headquartered CSL March 29 released its first Corporate Responsibility Report, combining information about the company's economic, social and environmental performance for 2009
CSL Posts 23 Percent Revenue Growth, Boosted Largely By H1N1 Sales
PERTH, Australia - Melbourne-headquartered CSL attributed its 23 percent revenue growth for the first half of 2010 to it's A/H1N1 vaccine Panvax out of its Biotherapies business unit. Business strategy for the company will focus on geographic expansion in emerging markets and specialty products